Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin Lymphoma (HL) and primary mediastinal B-cell lymphoma (PMBL) and survival in a lymphoma xenograft murine mouse: an AYA therapeutic opportunity [Meeting Abstract]
Levine, Selena R.; Shah, Tishi; Hochberg, Jessica; Ayello, Janet; Morris, Erin; de Ven, Carmella van; Cairo, Mitchell S.
Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults [Review]
Levine, Selena R.; McNeer, Jennifer L.; Isakoff, Michael S.
NEONATAL SUPRAVENTRICULAR TACHYCARDIA: RECURRENCE IN THE FIRST YEAR OF LIFE [Meeting Abstract]
Bonney, William; Levine, Selena R.; Kandlikar, Jyoti S.; Patel, Akash R.; Vogel, R. Lee; Shah, Maully J.; Iyer, Ramesh V.
Ventricular assist device-associated anti-human leukocyte antigen antibody sensitization in pediatric patients bridged to heart transplantation
O'Connor, Matthew J; Menteer, Jondavid; Chrisant, Maryanne R K; Monos, Dimitrios; Lind, Curt; Levine, Selena; Gaynor, J William; Hanna, Brian D; Paridon, Stephen M; Ravishankar, Chitra; Kaufman, Beth D
BACKGROUND:Ventricular assist devices (VAD) are associated with the formation of antibodies to anti-human leukocyte antigens (HLA) or sensitization. The incidence and effects of VAD-associated anti-HLA sensitization have not been well studied in the pediatric population. METHODS:A retrospective review of all patients undergoing VAD implant at our institution from 1998 to 2008 was performed. Panel reactive antibody (PRA) results before VAD implant, after VAD implant, and after orthotopic heart transplantation (OHT) were recorded. Patients who became sensitized (PRA for class I and/or II immunoglobulin G antibodies >or= 10%) on VAD support were compared with non-sensitized patients with regard to demographics, diagnosis, device type, and blood product exposure on VAD support. Outcomes after OHT were also compared between groups. RESULTS:VAD support was initiated in 20 patients (median age, 14.4 years), with 75% survival to OHT or recovery. PRA data before and after VAD implant were available for 17 patients. VAD-associated sensitization developed in 35% of recipients. There were no differences between those sensitized in association with VAD support and non-sensitized patients with regard to age, gender, diagnosis, device type, extracorporeal membrane oxygenation use, or blood product exposure on VAD support. Black race predicted sensitization on VAD (p = 0.02). There were no differences in survival or rejection between groups. CONCLUSIONS:VAD therapy was associated with the development of anti-HLA sensitization in 35% of recipients. Black race predicted sensitization, but there were no differences in overall survival or outcomes after OHT.
Too fat or too thin? Body habitus assessment in children listed for heart transplant and impact on outcome
Kaufman, Beth D; Nagle, Monica L; Levine, Selena R; Vijaynathan, Nirmala; Hanna, Brian D; Paridon, Stephen; Ravishankar, Chitra; Chrisant, Maryanne K
BACKGROUND:Body habitus assessment (BHA), be it wasted or obese, is a useful marker of nutritional status and overall medical condition. Wasting and obesity pre-heart transplant adversely affects outcomes in adults. The utility of BHA as a prognostic factor in children post-transplant is unknown. METHODS:Weight and height at listing and standard growth charts were used to determine the ideal body weight (%IBW) and percentiles for body mass index for age (BMI%) and weight-for-length (W:L%). Wasting was defined as <90%IBW and/or <or=5th percentile for BMI% or W:L%. Obesity was defined as >120%IBW and/or >or=95th percentile BMI% or W:L%. Outcomes of cohorts based on these criteria were compared. RESULTS:From June 1990 to December 2006, 180 children, aged 5.81 +/- 6 years, were listed for transplant. Wasting occurred in 66 (37%) and obesity in 22 (12%) children, without differences between diagnoses of cardiomyopathy or congenital heart disease. %IBW was a prognostic factor for survival post-transplant on multivariate analysis: obese patients had a hazard ratio (HR) of 3.82 (95% confidence interval [CI] 1.81 to 8.06) compared with normal BHA (p < 0.001). Wasting had a survival advantage compared with normal BHA (HR 0.51, 95% CI 0.27 to 0.94, p = 0.032). There were no significant differences between cohorts in incidence of infections, first-year rejections or graft vasculopathy. CONCLUSIONS:Abnormal BHA at listing was a prognostic factor for survival post-transplant. Obese children had increased mortality, but wasting did not adversely affect post-transplant survival in our population. Body habitus assessment may risk-stratify children at listing, potentially providing a complex target for intervention.